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Abstract
Background: Previous studies have extensively documented antimicrobial and chemotactic activities of beta-defensins.
Human beta-defensin-2 (hBD-2) is strongly expressed in lesional psoriatic epidermis, and recently we have shown that high
beta-defensin genomic copy number is associated with psoriasis susceptibility. It is not known, however, if biologically and
pathophysiologically relevant concentrations of hBD-2 protein are present in vivo, which could support an antimicrobial and
proinflammatory role of beta-defensins in lesional psoriatic epidermis.
Methodology/Principal Findings: We found that systemic levels of hBD-2 showed a weak but significant correlation with
beta defensin copy number in healthy controls but not in psoriasis patients with active disease. In psoriasis patients but not
in atopic dermatitis patients, we found high systemic hBD-2 levels that strongly correlated with disease activity as assessed
by the PASI score. Our findings suggest that systemic levels in psoriasis are largely determined by secretion from involved
skin and not by genomic copy number. Modelling of the in vivo epidermal hBD-2 concentration based on the secretion rate
in a reconstructed skin model for psoriatic epidermis provides evidence that epidermal hBD-2 levels in vivo are probably
well above the concentrations required for in vitro antimicrobial and chemokine-like effects.
Conclusions/Significance: Serum hBD-2 appears to be a useful surrogate marker for disease activity in psoriasis. The
discrepancy between hBD-2 levels in psoriasis and atopic dermatitis could explain the well known differences in infection
rate between these two diseases.
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Introduction
Psoriasis is a highly prevalent inflammatory skin disease that has
both environmental and genetic components to its etiology [1,2].
Genetic evidence for an (auto)immune basis of psoriasis is
provided by the well-known association of the disease with the
HLA-Cw6 gene [3] and the recently discovered associations with
IL12B and IL23R [4,5]. Lesional psoriatic skin is characterized by
various morphological abnormalities of the epidermis, and a
cellular infiltrate of activated T-cells. There are several arguments
to invoke an important role of activated T-cells such as the
oligoclonal T-cell expansion in psoriatic skin [6] and the
therapeutic efficacy of T-cell directed drugs such as cyclosporin
A and some of the biologics that are currently available. Recent
evidence also points to a role of other cell types such as
plasmacytoid dendritic cells [7], and cytokine networks associated
with cells from the adaptive and innate immune system [1,8].
Based on clinical studies in humans and experimental studies in
mice, several of these cytokines have been identified including IL-
1, TNFa, interferon-c and IL-6. In the epidermis a regenerative
epidermal differentiation program is induced that includes
hyperproliferation and expression of genes such as cytokeratin
16 (CK16), SKALP/elafin, psoriasin and hBD-2 [9,10]. Expres-
sion of these genes is to some extent specific for psoriasis, as they
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4725are expressed at low levels, if at all, in lesional atopic dermatitis
skin [11–13].
Recent findings from various labs including our own have
indicated that polymorphisms of genes that are expressed in the
epithelium, but not necessarily in immunocytes, could also be risk
factors for inflammatory skin diseases such as atopic dermatitis and
psoriasis [14–17]. This finding was further supported at the
cellular level when we found cell-autonomous differences between
keratinocytes from psoriasis and atopic dermatitis patients [18].
From these studies we concluded that psoriatic keratinocytes are
programmed to secrete large amounts of host defense proteins
such as beta-defensins, in response to Th1 or Th17 cytokines.
Beta-defensins are secreted peptides of low molecular weight
ranging from 3 to 5 kDa. These peptides, which are expressed by
epithelia, possess a broad spectrum of antimicrobial activity
against both gram-positive and gram-negative bacteria, fungi and
viruses [19]. Besides antimicrobial activity, they also exhibit pro-
inflammatory properties as chemoattractants for memory T-cells,
immature dendritic cells, mast cells and neutrophils [20–22].
These peptides, encoded by the DEFB genes, are present in three
main gene clusters, two on chromosome 20 and one on 8p23.1.
The cluster on 8p23.1 contains eight beta-defensin genes of which
seven (all but DEFB1) are on a large repeat that is variable in copy
number. In humans up to 12 copies of this repeat have been
found, with a mode of four copies per diploid genome [23]. Of the
eight beta-defensin genes located on 8p23.1, human beta-defensin-
1 (hBD-1) protein, (encoded by DEFB1) and hBD-3 (encoded by
DEFB103) are constitutively expressed at low levels in skin [24].
hBD-2 (encoded by DEFB4) is not expressed in normal skin but is
highly expressed in psoriatic skin. hBD-4 (encoded by DEFB104)i s
less well characterized at the protein level but is found in skin by
RT-PCR. hBD-2, hBD-3 and hBD-4 can be induced by cytokines
and bacterial lipopolysaccharides in various epithelial cell types
[25]. It has also been shown that antimicrobial peptides in general,
and above all hBD-2, are induced in lesional epidermal cells of
patients with psoriasis, compared with lesional epidermal cells of
patients with atopic dermatitis and normal skin [10,11]. These
findings have been interpreted to explain the observed high
infection rate in atopic dermatitis and the relatively low prevalence
of bacterial and viral infections among psoriasis patients [26].
In addition to their direct antimicrobial activity, the chemotactic
properties of antimicrobial proteins like LL-37 and beta-defensins
are thought to amplify leukocyte recruitment [27], thereby
contributing to an effective antimicrobial response. In non-
infectious inflammatory diseases like psoriasis, beta-defensins
could augment the influx of T-cells and dendritic cells, and
thereby contribute to chronicity and sustained disease. Although
the antimicrobial and chemotactic activities in vitro have been well
documented, there are no quantitative data on in vivo concentra-
tions of beta-defensins to substantiate a role of these molecules in
host defense or inflammation. In this study we have made a
detailed analysis of systemic and epidermal defensin concentra-
tions. We show that both genetic factors and disease activity
determine defensin protein expression. Evidence is provided that
the in vivo concentration of hBD-2 is well above the minimal
concentrations that are required for biological activity in vitro.
Materials and Methods
Patients and healthy subjects
All psoriasis patients had plaque-type psoriasis diagnosed by a
dermatologist. Atopic dermatitis was diagnosed by a dermatolo-
gist, according to the Hanifin criteria, and were of the extrinsic
type [28]. Rheumatoid arthritis patients were diagnosed by a
rheumatologist, according to the ACR criteria. Patients were
recruited via the in-patient or out-patient departments of the
Radboud University Nijmegen Medical Centre. Control sera and
DNA samples were from the Nijmegen Biomedical Study (NBS)
[29]. All controls and patients were of native European Dutch
origin. Demographic data were as follows (age: mean and SD, and
% female); Controls: 50616, 59% female; Psoriasis patients:
47613 year, 42% female; Rheumatoid arthritis patients:
5968 years, 66% female. Available information of medication
used during sample collection: 59% of the psoriasis patients were
on biologicals (all TNF-blockers) and 36% were on other types of
systemic medication (retinoids, MTX). Nearly all rheumatoid
arthritis patients used NSAIDs, 45% was on MTX and 25% was
on biologicals (various kinds, mostly TNF blockers). Blood was
stored at 280uC and genomic DNA was isolated by standard
procedures. Permission for these studies was obtained from the
local medical ethics committee (Commissie Mensgebonden
Onderzoek Arnhem-Nijmegen), and volunteers gave written
informed consent. The study was conducted according to the
Declaration of Helsinki principles.
Clinical scores
As a measure of disease severity the clinical score was
determined by medical specialists. For psoriatic patients the PASI
(0 to 72 scale) [30], for atopic dermatitis patients the SCORAD (0
to 103 scale) [31] and for rheumatic arthritic patients the DAS28
(0 to 10 scale) [32] was used to measure disease severity. Patients
were classified as being in remission, or having low disease activity,
moderate disease activity or high disease activity (see table 1).
Immunohistochemistry
Autopsy material and skin biopsies were fixed in 4% phosphate-
buffered formalin and embedded in paraffin as described before
[33]. Sections of seven micrometer were stained according to the
avidin biotinylated-enzyme-complex method (Vector Laborato-
ries, Burlingame, CA) using a goat anti-hBD-2 serum (Abcam,
Cambridge, UK).
RNA extraction and real-time quantitative polymerase
chain reaction
RNA from a variety of organs that included many epithelial
tissues, was available from autopsy material of one individual. For
this reason the qPCR data in figure 1 have only n=1 for most
organs. Additional RNA samples from lung (8), kidney (2), heart
(1), testis (1), spleen (1) and liver (1), normal (5) and inflamed
epidermis (7) and inflamed synovium (5) were obtained from
different individuals and analyzed for beta defensin expression.
Variability between the different samples from one type of organ
was low, and similar profiles of differential expression of beta
defensins 1, 2 and 3 were found. When multiple samples per organ
were available, expression values are given as mean and SD in
figure 1.
RNA was extracted from twenty-four different normal human
tissues, punch biopsies and cultured human keratinocytes, and first
strand cDNA was synthesized using an input of 1 mg of RNA with
the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) according
to the manufacturer’s recommendation. The reverse transcriptase
product was used as a template for quantitative real-time PCR
amplification of genes of interest hBD-1, hBD-2 and hBD-3 and
the housekeeping gene human ribosomal phosphoprotein P0
(RPLP0) with the MyiQ Single-Color Real-Time Detection
System for quantification with Sybr Green and melting curve
analysis (Biorad, Richmond, CA). Expression of target genes was
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Diagnosis Disease severity Disease score N Serum hBD-2 (ng/ml)
Controls n.a. n.a. 70 0.2160.17
Psoriasis remission, PASI 0–1 0.460.4 3 0.6460.36
low, PASI 1–10 6.062.7 18 4.564.6
moderate, PASI 10–20 15.162.8 12 11.569.1
high, PASI.20 30.263.6 5 84.2680.0
Atopic dermatitis remission, SCORAD 0–5 060 2 0.1060.01
low, SCORAD 5–15 12.062.8 2 0.1260.03
moderate, SCORAD 15–40 27.969.4 6 1.0560.95
high, SCORAD.40 47.665.0 2 1.3960.74
Rheumatoid arthritis remission, DAS28 0–2.6 2.160.5 10 0.3360.16
low DAS28, 2.6–3.2 2.960.1 5 0.3460.19
moderate, DAS28 3.2–5.1 4.260.6 16 0.5160.41
high, DAS28.5.1 6.060.4 9 0.8360.59
Serum hBD-2 levels were determined by ELISA. Analysis of variance on log transformed data showed that there was a significant correlation between disease severity
and serum hBD-2 levels in psoriasis patients (p,2610
25). Disease scores and serum hBD-2 concentration are given as mean and SD. n.a. not applicable.
doi:10.1371/journal.pone.0004725.t001
Figure 1. Analysis of beta-defensin mRNA expression in normal and inflamed human tissues. Quantitative real-time PCR was performed
on RNA of normal human tissues (mostly obtained from one individual), purified epidermis from skin biopsies of healthy controls, psoriasis patients
and atopic dermatitis patients, and inflamed synovium from rheumatoid arthritis patients. Expression of target genes was normalized to that of
RPLP0. For graphical representation all values were expressed relative to hBD-2 in tongue, which was set at unity [34]. Primer sequences and
efficiency of amplification are given in supplemental table S1. For details on normal human tissues see materials and methods. Bars represent mean
and SD.
doi:10.1371/journal.pone.0004725.g001
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found to be subject to regulation in keratinocyte cultures,
irrespective of stimulation or diagnosis, and is more reliable than
other reference genes such as ACTB (actin) or GAPDH (data not
shown). RPLP0 levels of the various tissues did not show large
differences (mean and SD of Ct values of normal human tissues
was 21.761.6). The deltaCt values were used for statistical
analysis. For graphical representation (figure 1) all values were
expressed relative to hBD-2 in tongue, which was set at unity [34].
This allows comparison of all genes and all tissues for relative
expression levels. Primer sequences (Biolegio, Nijmegen, The
Netherlands) and efficiency of amplification are given in
supplemental table S1.
Production of recombinant hBD-2 and rabbit antiserum
A hBD-2 PCR product from cDNA derived from cultured
keratinocytes was cloned into pGEX-2T vector (Amersham
Pharmacia Biotech, Uppsala, Sweden), expressed as a GST-
hBD-2 fusion protein in Escherichia coli and affinity-purified.
Commercial recombinant hBD-2 (Peprotech, Rocky Hill, NJ)
was cross-linked to ovalbumin, using glutaraldehyde, to increase
immunogenicity. This preparation was dialysed against phosphate-
buffered saline and emulsified with complete Freund’s adjuvant to
immunize rabbits to generate polyclonal serum. Animals were
boostered with GST-hBD-2, and blood was obtained for serum
preparation.
ELISA
Affinity-purified goat anti-hBD-2 (Abcam) was used to coat 96-
well microtiter plates. After blocking in 1% (v/v) bovine serum
albumin, serum samples were applied in a serial 2-fold dilution
range, followed by our rabbit anti-hBD-2 as a second antibody,
and detection by the ABC kit (Vector). All steps were followed by
appropriate washing in phosphate-buffered saline with 0.05% (v/
v) Tween-20. The serum hBD-2 concentrations were read from a
calibration curve of recombinant hBD-2 (Peprotech). The
detection limit of this ELISA was 0.03 ng/ml, using recombinant
hBD-2 (Peprotech) for calibration. Anti-hBD-2 antibodies were
checked for specificity against hBD-2, and we found that
recombinant hBD-1 (Abcam) and hBD-3 (Abcam) were not
recognized. We found no evidence for circadian differences in
serum hBD-2 in healthy individuals (data not shown). Serum hBD-
2 was found to be stable upon storage at 220uC. No large
differences were found for individuals from whom we had serum
samples taken with a two-year interval. Commercially available
ELISA kits for hBD-2 and hBD-3 were purchased from Phoenix
(Belmont, CA) and performed according to manufacturer’s
recommendations. The detection limits for these assays were
0.05 and 0.1 ng/ml respectively, using synthetic hBD-2 and hBD-
3 for calibration.
Genotyping of defensin copy number
Genomic DNA from seventy control individuals without
inflammatory skin disease was analyzed for genomic copy number.
Most of these individuals were analyzed by three methods:
MAPH, REDVR and PRT as described previously in great detail
[16,23,35]. These analyses were used to obtain the best estimate of
integral copy number.
Three-dimensional reconstructed skin
Reconstructed skin was generated as described before [36].
Briefly, de-epidermized human dermis (DED) of 0.8 mm thickness
and 8 mm diameter was used as a scaffold for keratinocytes in
tissue culture inserts in a 24-well plate. These were cultured
submerged for three days, and subsequently the medium level was
lowered to allow air-exposure to induce terminal differentiation.
After seven days of air exposure a fully stratified epidermis has
developed that expresses all normal differentiation markers, but is
negative for psoriasis-associated genes like CK16, SKALP/elafin
and hBD-2. At this point a mixture of 10 ng/ml IL-1a, 5 ng/ml
TNFa and 5 ng/ml IL-6 is added for 72 hours, which induces
high expression levels of psoriasis-associated genes. The culture
medium, 450 ml per culture, was harvested and changed at 24, 48
and 72 hours and used for hBD-2 ELISA. Two different donors
for human keratinocytes were used.
Statistics
All statistical analyses were performed using the Statistica
software package version 7, Statsoft Inc. Analysis of variance was
performed on log transformed data of serum hBD-2. Analysis of
qPCR data was done on deltaCt values.
Modelling of epidermal hBD-2 concentrations
Fick’s law for mass transport was applied. For the diffusion
coefficient (D) of hBD-2 we used 1.44610
210 m
2/sec as
experimentally determined for bovine pancreatic trypsin inhibitor
(BPTI) [37], a protein of similar mass and isoelectric point as hBD-
2, or we used an approximation based on Graham’s law using the
known value for BSA (10
210 m
2/sec). The hBD-2 production) in a
reconstructed skin model stimulated with proinflammatory
cytokines was used estimate the concentration in the epidermal
compartment in vitro, as an approximation of the concentration in
psoriatic epidermis. See supplemental text S1 and supplemental
figure S1 for details.
Results
Expression of beta-defensin mRNA and protein in normal
tissues and inflamed skin
Although expression of beta-defensins in some human tissues
has been documented before, we wanted to obtain a comprehen-
sive picture of beta-defensin tissue distribution in order to estimate
which specific tissues would contribute to systemic protein levels.
We performed a qPCR analysis of two beta-defensin genes that are
contained in the repeat on chromosome 8 (DEFB4 and DEFB103)
and one beta-defensin outside the repeat (DEFB1). Figure 1 shows
that hBD-1 mRNA is widely expressed whereas significant levels of
hBD-2 are predominantly found in oral epithelia. hBD-3 is
expressed more broadly than hBD-2 as it is also found at low levels
in normal epidermis and a few other tissues. As indicated in
figure 1 (log scale) hBD-2 expression levels in lesional psoriatic
epidermis are extremely high compared to any other tissue. hBD-2
mRNA expression in atopic dermatitis is also increased, compared
to normal skin where it is undetectable. We analyzed the
expression of hBD-2 at the protein level by immunohistochem-
istry. Figure 2A–E confirm the moderate expression levels in
tongue and plantar epidermis, and the absence of expression in
normal skin. The extremely high mRNA expression level in
psoriatic epidermis was indeed reflected by high levels of protein as
we have described before [10].
Serum hBD-2 levels in healthy volunteers correlate with
genomic copy number
As a next step we wanted to make a quantitative determination
of systemic defensin protein levels. Defensins are secreted proteins
that will easily pass basal membranes, and we expected that
b-Defensins in Psoriasis
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could be measured in serum by ELISA. On the basis of the limited
expression of hBD-2 in normal human tissues, as demonstrated in
figure 1, we expected low levels of protein in normal human
serum. We developed and validated an ELISA that was sensitive
and specific for hBD-2 to allow measurement of low serum hBD-2
levels. In addition, commercially available ELISA kits were used to
measure hBD-2 and hBD-3 protein in serum. We have previously
shown that most beta-defensin genes on 8p23.1 (including those
that encode hBD-2 and hBD-3) are subject to copy number
variation. So far no studies have been published that investigated
the relation between copy number and protein expression. Here
we selected 70 healthy individuals without inflammatory skin
disease, that were typed for beta-defensin copy number using
multiplex amplifiable probe hybridization (MAPH), restriction
enzyme digest variant ratio (REDVR) and paralogue ratio test
(PRT). In the normal population, copy number classes of 3 to 5
defensin repeats per diploid genome are the most prevalent. We
selected individuals to include sufficient numbers of the more rare
copy classes of 2 and 6 to allow analysis of correlation between
genomic copy number and serum hBD-2 protein. Figure 3 shows
that there is a modest but highly significant correlation between
copy number and hBD-2 protein concentration in serum. No
correlation between serum hBD-2 and age or gender was found.
Low hBD-2 levels were found up to 0.80 ng/ml in these human
sera (mean and SD: 0.2160.17 ng/ml, see table 1), but clearly the
variance is only partially explained by copy number. A similarly
weak correlation (Pearson’s R=0.4, p=0.001) between copy
number and serum protein was found using a commercially
available hBD-2 ELISA, although absolute levels of hBD-2
appeared to be higher for the commercial kit, which was probably
due to the difference in standards used (not shown). hBD-3 serum
levels of individuals without inflammatory skin disease were all
below the detection limit (0.1 ng/ml). These data show that hBD-2
(but not hBD-3) can be measured in normal human serum, and
that these uninduced levels are at least in part determined by
genomic copy number.
hBD-2 serum levels of psoriasis patients correlate with
clinical severity
Because of the modest expression of hBD-2 mRNA in most
normal tissues we expected relatively low levels of hBD-2 protein in
the circulation, as was indeed found by ELISA in control individuals
(figure 3). In view of the huge increase of hBD-2 mRNA in lesional
psoriatic epidermis, the inflamed skin of psoriasis patients was likely
to cause increased systemic levels of hBD-2 protein. We measured
hBD-2 in sera of 38 psoriasis patients in a range of clinical severity as
determined by the Psoriasis Area and Severity Index (PASI) score
(see table 1). We could indeed demonstrate high levels of serum
hBD-2 in psoriasis patients, which were found to be about 400-fold
increased in severely affected patients compared to healthy
individuals (see table 1). A significant effect of disease severity on
serum hBD-2 was found by analysis of variance (p,2610
26).
Figure 4 shows that there is a strong linear correlation between PASI
score and the log-transformed serum hBD-2 concentration. Strongly
increased levels were also found in the urine of psoriasis patients
whereas hBD-2 could not be detected in urine of healthy controls.
Urinary hBD-2 levels were showed strong interindividual variation
(2.2+3.2 ng/ml). These findings suggest that increased systemic
levelsare derived fromhigh cutaneousproduction. It isobviousfrom
figure 4 that the clinical severity in psoriasis patients is a far stronger
determinant of hBD-2 serum concentration than copy number for
uninduced levels in healthy controls (figure 3). There were
insufficient numbers of informative psoriasis patients from whom
defensin copy numbers and PASI scores were available, to make a
reliable estimate of the effect of copy number and disease severity on
hBD-2 levels. Remarkably, onlyina minorityof psoriasis patientswe
could demonstrate hBD-3 levels that exceeded the detection limit of
the assay (not shown).
To investigate if high systemic hBD-2 levels could be caused by
inflammation per se, irrespective of the tissue localization, we
compared serum hBD-2 levels in psoriasis patients with that of 40
patients with rheumatoid arthritis (RA). Low hBD-2 serum levels
Figure 2. Immunolocalization of hBD-2 in human epithelia. Immunohistochemical staining of normal human tissues (tongue, plantar skin and
trunk skin, A–C) with a polyclonal rabbit antiserum against recombinant hBD-2. Note that protein data largely follow the mRNA data demonstrating
the absence in normal skin, low expression in tongue and plantar skin. Bar=100 mm. Control sections stained with pre-immune serum were negative
(not shown).
doi:10.1371/journal.pone.0004725.g002
Figure 3. Correlation between serum hBD-2 protein levels and
genomic copy number. Serum hBD-2 protein levels of 70 healthy
controls (determined by ELISA) were plotted against the genomic copy
number of the beta-defensin repeat on chromosome 8p23, as
determined by MAPH, REDVR and PRT. A significant linear correlation
was found. Pearson’s R=0.46 and p,7610
25.
doi:10.1371/journal.pone.0004725.g003
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RA patients that were in remission (see table 1). In the combined
RA patients with moderate to high disease activity, a small but
significant increase of serum hBD-2 was found compared to the
control group (t-test, p,10
25). qPCR analysis of synovial tissue
from RA patients with active disease showed that the synovium is
unlikely to be the source of this small increase in hBD-2 protein, as
no mRNA for hBD-2 could be detected (see figure 1). No
significant correlation was found between serum hBD-2 and
clinical severity as determined by Disease Activity Score (DAS28).
As previously reported [10], hBD-2 protein is expressed at low
to undetectable levels (immunohistochemistry) in lesional atopic
dermatitis, despite strong induction at the mRNA level. In sera
from 8 patients with moderate to severe atopic dermatitis we found
that, although serum hBD-2 levels were significantly higher than
in control sera (t-test, p,10
25), they were far lower than in sera of
psoriasis patients of similar disease severity (see table 1). A
significant linear correlation between log-transformed serum hBD-
2 and atopic dermatitis disease severity, as determined by
SCORing Atopic Dermatitis (SCORAD), was found (Pearson
r=0.7, p,0.01), suggesting that also in atopic dermatitis increased
systemic levels are derived from increased cutaneous production.
Serum hBD-2 is a disease marker in individual psoriasis
patients
As serum hBD-2 showed a correlation with disease activity over a
group of psoriasis patients, we next investigated if hBD-2 levels
correlatewith clinicalstatusofindividual patients.Serum hBD-2 was
measured in 15 patients that participated in clinical studies for which
PASI scores and serum was available on two different occasions over
a 6–18 week interval. Figure 5 shows that there is a strong
correlation between the change in hBD-2 (DhBD-2) and change in
PASI score (DPASI) in eleven patients that showed clinical
improvement and four patients that showed exacerbation of disease.
Estimation of in vivo hBD-2 concentration in psoriatic
epidermis using in vitro reconstructed skin
The high serum levels of hBD-2 in psoriasis patients (up to
190 ng/ml), which we interpret to be derived from local production
by the keratinocytes, suggest that the concentrations to which
keratinocytes and infiltrated cells in the epidermis and papillary
dermis are exposed must be several orders of magnitude higher.
Based on in vitro studies, the concentrations required to have a
relevant biological effect would vary between 0.1 and 100 mg/ml.
Because these local tissue concentrations are difficult to estimate
directly from in vivo data, we measured the production of hBD-2 in
reconstructed skin as a model for human epidermis. Human
reconstructed skin equivalents were obtained as described previously
[38], and stimulated with IL-1a,T N F - a and IL-6. This cytokine
mixture was recently found to be optimal for induction of a psoriatic
phenotype in vitro, as witnessed by high expression levels of CK16,
SKALP/elafin and hBD-2 [36]. qPCR analysisofisolatedepidermal
sheets indicated that hBD-2 mRNA levels (determined as deltaCt
values)intheseculturesweremuchhigherthaninkeratinocytesfrom
submerged cultures (not shown), and reached similar high values as
found in epidermal sheets from lesional psoriatic skin (see figure 1).
Figure 6 shows hBD-2 protein expression by differentiated
keratinocytes in the reconstructed skin model stimulated with pro-
inflammatory cytokines. We collected culture medium from
cytokine-stimulated reconstructed skin of two donors during
24 hours starting two days after addition of the cytokine mix. Using
Figure 4. Correlation between serum hBD-2 protein and PASI
score. Serum hBD-2 protein levels of 38 psoriasis patients of varying
disease severity were plotted against their PASI score. A significant
linear correlation was found. Pearson’s R=0.82, p,4610
210.
doi:10.1371/journal.pone.0004725.g004
Figure 5. Correlation between the change in serum hBD-2
concentration and change in clinical score. Serum hBD-2 protein
levels of 15 patients for which PASI scores and serum was available on
two different occasions over a 6–18 week interval, were plotted against
the change in PASI score (DPASI). A significant linear correlation was
found. Pearson R=0.74, p,0.002. Note that there was a decrease in
serum hBD-2 in most patients that showed clinical improvement
(negative DPASI) and an increase in serum hBD-2 in a few patients that
showed exacerbation (positive DPASI).
doi:10.1371/journal.pone.0004725.g005
Figure 6. Induction of hBD-2 protein expression in reconstruct-
ed skin by proinflammatory cytokines. Expression of hBD-2 in 3-D
reconstructed skin following stimulation with psoriasis-associated
cytokines (10 ng/ml IL-1a, 5 ng/ml TNFa and 5 ng/ml IL-6) for 72 hours.
Note that without stimulation there is no hBD-2 expression (A), whereas
the cytokine mixture induces high expression levels that are secreted
into the underlying culture medium (147 ng/ml in 24 h). Part of the
hBD-2 protein remains adsorbed to the dermal matrix as witnessed by
the staining of structures in the dermis (B). Bar=100 mm.
doi:10.1371/journal.pone.0004725.g006
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skin constructs, secreted approximately 66619 ng hBD-2 per
24 hours into the tissue culture medium (mean and SD of four
cultures). We derived the local epidermal concentration using an
approximation based on the known diffusion coefficient of a small
cationic protein in aqueous solution (see supplemental materials for
assumptions and dimensions of the system, used for modelling).
Alternatively, a theoretical value for the diffusion coefficient was
obtained based on Graham’s law (see supplemental materials). The
most conservative estimation of the hBD-2 local concentration in the
compartment of the epidermis was 1.2 mg/ml (0.3 mM), which is
far higher than concentrations required for in vitro antimicrobial
activity, or those reported for chemotactic activity towards T-cells
and dendritic cells.
Discussion
Psoriasis is associated with increased beta-defensin genomic
copy number but no quantitative information on defensin protein
expression in vivo, as a function of copy number or disease status
was available. We now present evidence that both genomic copy
number and epidermal activation by psoriasis-associated cytokines
determine expression levels of hBD-2. We conclude that these
increased circulating hBD-2 levels in patients are derived from
cutaneous production, indicating that local hBD-2 concentrations
in psoriatic epidermis are likely to be extremely high. Extrapola-
tion from an in vitro model system suggests that the concentration
in the epidermis or papillary dermis (0.3 mM) by far exceeds the
concentrations required to be antimicrobial (2.5 to 25 mM) and
chemotactic in vitro (250 nM) as described previously by others
[9,39].
A number of studies have reported expression of human beta-
defensins in various tissues, including normal skin, inflamed skin
and non-cutaneous epithelia, using semi-quantitative RT-PCR or
immunohistochemistry. Here we have quantified circulating levels
of hBD-2 and hBD-3 by ELISA in healthy volunteers and patients
with inflammatory diseases. To assess which of the normal human
epithelia would contribute to steady state systemic protein levels,
we first performed a comprehensive qPCR analysis of the three
major epidermal defensins, hBD-1, -2 and -3 in a large panel of
human tissues. As shown in figure 1, hBD-1 mRNA is widely
expressed, and is not subject to regulation by inflammation, as it is
not highly induced in psoriatic skin. Measurement of hBD-1
protein in serum would have provided a reference value for a beta-
defensin that is expected to be rather constant as it is not present
on the psoriasis-associated repeat. We were however unsuccessful
in measuring hBD-1 protein by ELISA (not shown). hBD-2
mRNA appears to be expressed constitutively by a few tissues (e.g.
oral epithelia), and was indeed found at the protein level albeit
weakly (figure 2). hBD-2 is absent from normal trunk skin, but it is
expressed at low levels in plantar skin. Consequently, serum hBD-
2 levels in healthy individuals are very low (less than 1 ng per ml).
In addition to our own ELISA (recombinant hBD-2 for
calibration), we also used a commercial hBD-2 ELISA kit that
uses synthetic hBD-2 for calibration. Although there was a good
correlation between the data of both assays (Pearson r=0.9), the
commercial ELISA yielded apparent hBD-2 serum concentrations
10-fold higher than our ELISA. We found that this was caused by
a difference in immunoreactivity of the calibration standards used.
We used the values obtained with recombinant hBD-2 throughout
this paper, as a conservative estimate of hBD-2 concentration.
As shown in figure 3, genomic copy number only explains part
of the variance in serum hBD-2 levels. This is unlikely to be caused
by experimental error. We considered sampling error as a
potential cause, but we did not find variation in serum hBD-2
level depending on the time of blood sample collection (early
morning versus late afternoon). Longitudinal data showed only
minor fluctuation of serum hBD-2 levels in blood taken with two-
year intervals (not shown). We speculate that the large variation of
protein levels in each copy class could be caused by variation in
expression regulation, or alternatively, by genetic variation in the
defensin copies themselves. Although there is currently no
information on the existence of non-functional gene copies within
the repeat, this would obviously affect the gene-protein correla-
tion, and it could also affect the observed association with
psoriasis, which clearly requires further investigation.
Although our findings indicate that uninduced hBD-2 produc-
tion is subject to gene dosage effects, the high systemic serum levels
in psoriasis patients are caused by disease activity itself. We think
this indicates that hBD-2 can be used as an objective, quantitative
marker for disease activity in psoriasis. There are very few reliable
serum markers for disease activity in psoriasis. Candidate proteins
that are overexpressed in lesional epidermis include SKALP/elafin
and psoriasin/S100A7, but only SKALP/elafin was found to
correlate with disease activity [40,41]. Previous studies have
suggested that conventional surrogate markers for disease activity
in rheumatoid arthritis and psoriatic arthritis, such as erythrocyte
sedimentation rate and levels of C-reactive protein (CRP) are not
useful for chronic plaque psoriasis [42]. For this reason we looked
at the correlation between PASI scores and CRP in a cohort of our
own patients that were monitored over time. We did not find a
significant correlation between CRP and PASI for 1305 patient
visits (data not shown), again suggesting that serum hBD-2 could
be a convenient way to monitor disease activity or therapeutic
effects.
At the tissue level, hBD-2 secretion will be determined both by
copy number and by stimulation with proinflammatory cytokines.
Our data also suggest that disease activity in atopic dermatitis is
correlated with serum hBD-2. However, the epidermal expression
in atopic dermatitis is far lower than in psoriasis [10,11],
presumably resulting from the distinct cytokine environments of
these diseases [8,28]. We could indeed show that Th2 cytokines do
not induce hBD-2 expression in cultured keratinocytes [18] and
that Th2 cytokines repress the Th1 induced expression (not shown
here), as was previously shown for hBD-3 [43]. An additional level
of regulation of hBD-2 expression is the responsiveness of cells to
pro-inflammatory cytokines. We have recently shown that cell-
autonomous differences exist between keratinocytes of psoriasis
patients, atopic dermatitis patients and controls with respect to
innate immune responses following Th1 cytokine stimulation [18]
. We would speculate that there are apparently three mechanisms
that contribute to high levels of hBD-2 in psoriatic epidermis: a
dominant Th1 or Th17 cytokine profile, increased cell-autono-
mous responsiveness to cytokine stimulation, and high defensin
genomic copy number. Although defensins are endowed with
cytokine-like properties themselves, there is no information on a
possible autocrine effect of hBD-2 on keratinocytes whereby it
would induce or sustain its own production. This is clearly an area
worth investigating.
Several studies have demonstrated the biological activities of
human and mouse beta-defensins, such as antimicrobial activity
[9], chemotaxis of T-cells and dendritic cells [44], and activation
of TLR4 [45]. In general, many antimicrobial proteins appear to
be endowed with other immune-modulatory activities [46–48].
These findings have raised the intriguing possibility that beta-
defensins are part of the innate immune system that provides a link
between the epithelium and the adaptive immune system. This
would fit the emerging concept of inflammatory epithelial diseases
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dermatitis [15], Crohn’s disease [49] and celiac disease [50]. This
would also explain the clinical observation that both T-cell
directed drugs (cyclosporine A, UVB, some biologicals) and
keratinocyte-directed drugs (retinoids, vitamin D3 derivatives) are
effective in the treatment of psoriasis.
The defensin concentrations used in in vitro studies to
demonstrate their biological activity and their relevance for the
in vivo situation, should be interpreted with some caution. For
example, the antimicrobial activity of hBD-2 can only be
demonstrated at low salt conditions [51], at least in low
micromolar concentrations. Notwithstanding these considerations,
we attempted to make an estimate of the actual hBD-2
concentration in an active psoriatic lesion. Although there are
some caveats associated with modelling of the in vivo tissue
concentrations based on an in vitro reconstructed skin model, it is
clear that the hBD-2 levels in epidermis and papillary dermis are
well above the minimal concentrations that would cause a
biological effect in an experimental setting, even allowing for an
error of one order of magnitude. Remarkably, we found very little
hBD-3 protein in the circulation. Only in a few psoriasis patients
we observed detectable levels up to 0.5 ng/ml, which is 160-fold
lower than the hBD-2 concentration in patients with severe
psoriasis. Whether this also reflects low hBD-3 protein production
in the epidermis requires further investigation.
Our previous finding on the genetic association of psoriasis with
the defensin cluster did not allow discrimination between the seven
defensins or defensin-like genes contained in the repeated segment.
On the basis of available expression data we predicted that hBD-2
and hBD-3 would be the best candidates. Here we provide further
evidence that, based on copy number dependent and disease-
specific gene expression, high cutaneous protein levels and its
known proinflammatory properties, hBD-2 is one of the strongest
psoriasis candidate genes contained in the beta defensin cluster on
chromosome 8.
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